Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the greatest unmet needs. Furthermore, given that none of the currently available CHF treatments has proven outcome benefits in HFpEF patients, who constitute approximately 50% of CHF cases, a significant unmet need lies with this patient population. Therefore, significant clinical and commercial opportunities persist for therapies that can improve outcomes in this heterogeneous patient population.

Table of contents

  • Heart Failure - Unmet Need - Detailed, Expanded Analysis Chronic Heart Failure (US/EU)
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Chronic Heart Failure
        • Importance of Efficacy Attributes to Prescribing Decisions in Chronic Heart Failure: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Chronic Heart Failure: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Chronic Heart Failure: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Chronic Heart Failure: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Chronic Heart Failure: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Chronic Heart Failure: Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Chronic Heart Failure: United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Chronic Heart Failure: Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Chronic Heart Failure: United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Chronic Heart Failure: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Product for CHF
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Chronic Heart Failure: United States
        • Overall Performance of Key Therapies for Chronic Heart Failure: Europe
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Non-Clinical Attributes: United States
        • Relative Performance of Key Therapies for Chronic Heart Failure Across Select Non-Clinical Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Cardiologists' Satisfaction With the Performance of Key Therapies for Chronic Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: United States
        • Surveyed Cardiologists' Satisfaction With the Performance of Key Therapies for Chronic Heart Failure on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: Europe
      • Physician Rating of Unmet Need in Chronic Heart Failure
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Chronic Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Chronic Heart Failure: Europe
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Chronic Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Chronic Heart Failure: Europe
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Chronic Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Chronic Heart Failure: Europe
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Chronic Heart Failure: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Chronic Heart Failure: Europe
      • Unmet Need in Chronic Heart Failure and Related Indications
        • Surveyed Cardiologists' Ascribed Level of Unmet Need in Chronic Heart Failure and Related Indications: United States
        • Surveyed Cardiologists' Ascribed Level of Unmet Need in Chronic Heart Failure and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Chronic Heart Failure Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent That Improves Outcomes in HFpEF Patients
        • Opportunity: A New Therapy That Improves Outcomes In HFrEF Patients
        • Opportunity: A Novel Agent With Reduced Incidence Of Worsening Renal Function
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Chronic Heart Failure Target Product Profile: Attribute Importance
        • Chronic Heart Failure Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Chronic Heart Failure Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Chronic Heart Failure Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Chronic Heart Failure Market Simulations: Target Product Profiles Included in Scenario 1
        • Chronic Heart Failure Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Chronic Heart Failure Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Chronic Heart Failure Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Dominika Rudnicka-Noulin, PhD, MSc

Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.

Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions


Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details